NTLA - Intellia Therapeutics, Inc.
After hours:
| Previous Close | 41.27 |
| Open | 41.26 |
| Bid | 43.10 x 1100 |
| Ask | 43.75 x 3100 |
| Day's Range | 41.14 - 43.76 |
| 52 Week Range | 32.44 - 76.45 |
| Volume | |
| Avg. Volume | 1,044,819 |
| Market Cap | 3.845B |
| Beta (5Y Monthly) | 1.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.81 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 87.71 |
GlobeNewswireIntellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that Jean-François Formela, M.D. is retiring from its board of directors, effective June 15, 2023. "Working with the team at Intellia and seeing the company’s transformation from an idea to a leader in genome editing has been one of the most excit
Motley FoolWall Street Says These 2 Stocks May Double. Should You Buy Them?
One of the exciting parts of investing is identifying companies that will offer us the next big thing. This could be a game-changing drug or an exciting technology that may transform healthcare. And two companies Wall Street is bullish on have that potential.
- GlobeNewswire
Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023
Late-breaking presentation will include new safety, kallikrein reduction and attack rate data across all dose cohorts in the Phase 1 portion of the studyIntellia to host investor webcast on Monday, June 12, at 8 a.m. ET CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced the acceptance of a late-breaki
Motley FoolCathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You?
Cathie Wood looks for stocks that are leading innovators. But the stocks that fit that mold aren't always leaders when it comes to delivering huge returns over the short term. On the contrary, quite a few of the stocks in Wood's Ark Invest portfolios have been big losers.
ZacksAre You Looking for a Top Momentum Pick? Why Intellia Therapeutics, Inc. (NTLA) is a Great Choice
Does Intellia Therapeutics, Inc. (NTLA) have what it takes to be a top stock pick for momentum investors? Let's find out.
ZacksWall Street Analysts Think Intellia Therapeutics, Inc. (NTLA) Could Surge 115.12%: Read This Before Placing a Bet
The consensus price target hints at an 115.1% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ZacksIntellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update
Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.
ZacksIntellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 17.02% and 4.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023Plans to submit IND application in mid-2023 for a global pivotal study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023, subject to regulatory feedbackOn track to present additional clinical data in 2023 from both ongoing NTLA-2001
- GlobeNewswire
Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities
CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today released its 2023 Corporate Responsibility report. The report provides a comprehensive update of the Company’s performance and progress across key Environmental, Social and Governance (ESG) areas of focus. “As the leaders in a new era of medicine, we believe ES
Motley FoolCathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor has stumbled after a hot start to 2023, but Wood keeps adding to some of her favorite positions.
- GlobeNewswire
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates
CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2023 financial results and operational highlights in a conference call on May 4, 2023, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five
- GlobeNewswire
Intellia Therapeutics Names Bill Chase to its Board of Directors
CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced the appointment of Bill Chase, MBA, to its board of directors. Mr. Chase will be a member of the audit committee and will succeed Caroline Dorsa as chair of the audit committee upon her retirement from the board. Ms. Dorsa is retiring from Intellia’
Motley Fool2 Monster Growth Stocks That Can Double in Value, According to Wall Street
These stocks have some promising growth opportunities, but they also come with a fair amount of risk.
Simply Wall St.Investors push Intellia Therapeutics (NASDAQ:NTLA) 3.5% lower this week, company's increasing losses might be to blame
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...
ZacksIntellia's (NTLA) HAE Therapy Granted RMAT by the FDA
Intellia Therapeutics' (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, gets Regenerative Medicine Advanced Therapy designation for the treatment of hereditary angioedema.
- GlobeNewswire
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema
CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed t
Motley Fool3 Beaten-Down Stocks That Could Soar This Year
Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Exelixis (NASDAQ: EXEL), and Intellia Therapeutics (NASDAQ: NTLA). Prosper Junior Bakiny (CRISPR Therapeutics): Unprofitable clinical-stage biotech companies got hammered last year. Gene-editing specialist CRISPR Therapeutics fits that description to a T, so it got dragged down along with the broader market.
Motley FoolGot $2,000? 3 Growth Stocks to Buy That Could Double Your Money
There are no guarantees that any stock will generate huge returns. But the odds look pretty good for these three growth stocks.
Motley Fool2 Cathie Wood Stocks That Have Tripled Since the 2020 Market Crash
Cathie Wood's favorite stocks have been synonymous with growth, and although many of them have been struggling of late, there are a couple that have tripled in value in the past three years: Tesla (NASDAQ: TSLA) and Intellia Therapeutics (NASDAQ: NTLA). Since March 2020, shares of Tesla have soared 334%. Tesla also ended up joining the S&P 500 late in 2020 in a sign of its growing stability.
Motley FoolWhy Intellia Therapeutics Stock Jumped This Week
Shares of the gene-editing pioneer Intellia Therapeutics (NASDAQ: NTLA) rose by 17.5% through the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. There are currently eight medications approved by the FDA to prevent and/or treat HAE attacks. NTLA-2002, however, could be the first genetic medicine for this indication (depending on its ongoing clinical trials).
- GlobeNewswire
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)
NTLA-2002 is a single dose, in vivo genome editing candidate designed to prevent potentially life-threatening swelling attacks in people with HAECAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND
ZacksIntellia's (NTLA) Q4 Loss Matches Estimates, Revenues Up Y/Y
Intellia Therapeutics (NTLA) reports loss for fourth-quarter 2022, in line with estimates.
ZacksIntellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 0% and 11.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress
Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary angioedema (HAE)Submitted IND application for NTLA-2002 to enable patient enrollment in the U.S. for the Phase 2 study Plans to submit IND application in mid-2023 for global pivotal study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy; global pivotal study initiation anticipated by year-end 2023On track to present additional clinical data in 2023
